China Resources Pharmaceutical Group (3320) H1 2025 earnings summary

Executive summary

• Operating revenue grew 2.5% year-over-year to RMB131.87 billion in 1H2025, with gross profit up 2.8% and gross margin stable at 16.3%.

• Net profit declined 8.8% to RMB5.05 billion, mainly due to one-off impairment losses; adjusted net profit (excluding non-recurring items) fell 1.3%.

• Maintained top 3 industry ranking, with strong brand recognition and continued expansion in pharmaceutical manufacturing, distribution, and retail.

• Focused on innovation, external development, and operational excellence, including major acquisitions, R&D advancements, and digital transformation.

• Interim dividend declared at RMB0.072 per share, down from RMB0.083 last year.

Financial highlights

• Revenue: RMB131.87 billion (+2.5% YoY); gross profit: RMB21.51 billion (+2.8% YoY); gross margin: 16.3%.

• Net profit: RMB5.05 billion (-8.8% YoY); net profit attributable to owners/shareholders: RMB2.08 billion (-20.3% YoY); basic EPS: RMB0.33 (vs. RMB0.41 in 1H2024).

• Adjusted net profit (excluding one-off items): -1.3% YoY.

• Operating cash flow improved to RMB1.53 billion from -RMB1.02 billion in 1H2024.

• Interim dividend payout ratio at 22%.

Outlook and guidance

• Strategic focus on innovation-driven growth, portfolio optimization, and external expansion through M&A and industrial funds.

• Plans to enhance business in TCM, chemical drugs, biological products, specialty drugs, and high-end medical devices.

• Continued investment in R&D, digitalization, AI, and smart manufacturing to drive future growth.

• Commitment to operational excellence and prudent treasury management.